January 19, 2022 07:13 AM EST

AstraZeneca rolls out 'unprecedented' 3-year survival data for PD-L1/CTLA4 combo in liver cancer

Amber Tong

Months after AstraZeneca touted a major overall survival win for its Imfinzi/tremelimumab combo, the company is ready to spell out what it calls “unprecedented” results …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca rolls out 'unprecedented' 3-year survival data for PD-L1/CTLA4 combo in liver cancer

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

As­traZeneca rolls out 'un­prece­dent­ed' 3-year sur­vival da­ta for PD-L1/CT­LA4 com­bo in liv­er can­cer

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

AstraZeneca rolls out 'unprecedented' 3-year survival data for PD-L1/CTLA4 combo in liver cancer

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months